title: Efficient delivery of therapeutic agents by using targeted albumin nanoparticles.
abstract: Albumin nanoparticles are one of the most important drug carriers for the delivery of therapeutic drugs, especially for the treatment of malignancies. This potential is due to their high binding capacity for both hydrophobic and hydrophilic drugs and the possibility of surface modification. Accumulation of albumin-bound drugs in the tumor interstitium occurs by the enhanced permeability and retention effect, which is also facilitated by the 60-kDa glycoprotein transcytosis pathway and binding to secreted protein, acidic and rich in cysteine located in the tumor extracellular matrix. In addition, specific ligands such as monoclonal antibodies, folic acid, transferrin, and peptides can be conjugated to the surface of albumin nanoparticles to actively target the drug to its site of action. The albumin-bound paclitaxel, Abraxane, is one of the several therapeutic nanocarriers that have been approved for clinical use. By the development of Abraxane that demonstrates a higher response rate and improved tolerability and therapeutic efficiency in comparison with solvent-based formulation, and with consideration of its commercial success, albumin is attracting the interest of many biotechnological and pharmaceutical companies. This chapter explores the current targeted and nontargeted albumin-based nanoparticles that are in various stages of development for the delivery of therapeutic agents in order to enhance the efficacy of cancer treatment.
authors.affiliation: Biotechnology Group, Chemical Engineering Faculty, Tarbiat Modares University, Tehran, Iran.
authors.forename: Hasan
authors.initials: H
authors.lastname: Kouchakzadeh
authors.affiliation: Biotechnology Group, Chemical Engineering Faculty, Tarbiat Modares University, Tehran, Iran.
authors.forename: Maryam Sadat
authors.initials: MS
authors.lastname: Safavi
authors.affiliation: Biotechnology Group, Chemical Engineering Faculty, Tarbiat Modares University, Tehran, Iran. Electronic address: shoja_sa@modares.ac.ir.
authors.forename: Seyed Abbas
authors.initials: SA
authors.lastname: Shojaosadati
mesh_terms: D000068196:Albumin-Bound Paclitaxel / Q000737:chemistry / Q000627:therapeutic use*; D000418:Albumins / Q000737:chemistry*; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000378:metabolism; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems / Q000379:methods*; D005109:Extracellular Matrix / Q000737:chemistry / Q000378:metabolism; D005492:Folic Acid / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D058990:Molecular Targeted Therapy; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017239:Paclitaxel / Q000737:chemistry / Q000627:therapeutic use; D014168:Transferrin / Q000737:chemistry / Q000378:metabolism
chemical_list: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014168:Transferrin; D005492:Folic Acid; D017239:Paclitaxel
keywords: Abraxane®; Active targeting; Albumin nanoparticles; Desolvation; EPR effect; Monoclonal antibody; NAB technology